Janine Erler is a star of Danish cancer research, funded by ERC. Her earlier research led to the discovery of the key role of the enzyme lysyl oxidase in cancer metastasis and brought the scientist and businesswoman very close to curing cancer. Until some sad envious bad-wishers found duplicated gel bands in Erler papers.
What with the EU phase 2 clinical trial TETRA going nowhere, the technology’s owner, Liverpool-based company Videregen decided to seek new clinical partners. Surgeons and universities from outside the EU are invited to test Videregen’s trachea transplant technology, which was originally developed together with Paolo Macchiarini by the UCL laryngologist and paid Videregen advisor Martin Birchall.
German diabetologist Kathrin Maedler is a central figure of a questionable academic dynasty. Using Photoshop simulations, she discovered a cure for diabetes, which was then allegedly validated in clinical trials led by her Swiss PhD advisor Marc Donath. 15 years later, the Maedler-Donath diabetes cure was proven as utterly ineffective by same Donath, in another clinical trial. Maedler’s own PhD student, Amin Ardestani is group leader in Bremen, despite data irregularities and unacknowledged textual reuse in his thesis.
The European Commission admitted that their €6.8 mn phase 2 clinical trial TETRA with cadaveric tracheas, led by the UCL laryngologist Martin Birchall is unlikely to ever recruit any patients. In January 2019, the status was changed to “grant agreement terminated”
Swedish start-up Verigraft received €2.2 Million from European Union, to further develop regenerative medicine technology tainted by research misconduct and patient abuse. The founder of this very company: Suchitra Sumitran-Holgersson. A clinical trial is scheduled based on debunked science of recellurising dead blood vessel grafts.